Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical (Nasdaq: COLL) announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of a larger $100 million share buyback program authorized in August 2021. Upon completion of this ASR, Collegium will have approximately $52.2 million remaining under the buyback authorization. The ASR involves repurchasing around 1,026,694 shares at the $19.48 closing stock price as of November 12, 2021. This move reflects management's confidence in the business and commitment to enhancing shareholder value.
Collegium Pharmaceutical, a leader in responsible pain management, announced its participation in upcoming investor conferences. Management will attend the Jefferies London Healthcare Conference with virtual one-on-one meetings on November 18, 2021, and the Piper Sandler Annual Healthcare Conference featuring a virtual fireside chat on December 1, 2021. The fireside chat will be accessible via the Investor section of their website, with a replay available for 30 days post-event. For more information, visit Collegium's website.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will host virtual one-on-one meetings on November 18, 2021. Additionally, the Piper Sandler Annual Healthcare Conference 2021 will feature a virtual fireside chat on December 1, 2021. The fireside chat will be webcast, and a replay will be available on the company's Investor section website for 30 days following the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported a net income of $8.0 million and adjusted EBITDA of $37.3 million for Q3 2021. The company's Board has authorized a $25 million accelerated share repurchase, part of a broader $100 million initiative. Collegium aims for record full-year revenue and profits, driven by a strong pain management portfolio. Xtampza ER reached a 32.5% market share in ER oxycodone, while the Nucynta franchise exceeded $150 million in revenue. The company updated its 2021 financial guidance, adjusting Xtampza ER expected revenues down to $130-$135 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Investors can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers, referencing the "Collegium Pharmaceutical Q3 2021 Earnings Call." The webcast will be available on the company's website for replay shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) presented four poster sessions at the Annual PAINWeek National Conference, emphasizing its commitment to responsible pain management.
The presentations focused on the misuse and abuse of its products, particularly XTAMPZA® ER and Nucynta®, and provided real-world data on their diversion and non-medical use.
These efforts highlight the company's dedication to scientific research and education among healthcare providers, reinforcing its position in the pain management sector.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in two upcoming investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a fireside chat on September 13, 2021, from 7:00 to 7:30 AM Eastern Time. Additionally, Collegium will present at the Cantor Virtual Global Healthcare Conference on September 28, 2021, from 8:00 to 8:30 AM Eastern Time. Both presentations will be accessible via the company's investor website, with replays available for 30 days post-event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a $100 million share repurchase program, reflecting confidence in its growth and pain management portfolio. CEO Joe Ciaffoni emphasized their solid financial position and commitment to disciplined capital allocation. The program allows management flexibility in repurchasing shares based on market conditions and business needs, which could enhance shareholder value over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong financial results for Q2 2021, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza® ER achieved a market share of 31.5% in the oxycodone extended-release market, marking a significant growth from 30.6% in March 2021. However, the company adjusted its revenue guidance downwards for Xtampza ER to $140.0-$150.0 million, while increasing guidance for the Nucynta Franchise to $195.0-$205.0 million. A conference call is scheduled for today at 4:30 p.m. ET to discuss these results further.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on August 5, 2021, at 4:30 PM ET to discuss its financial results and corporate updates. Investors can participate by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international participants. A live webcast will be available on the company's website, with a replay accessible approximately two hours post-event. Collegium is committed to responsible pain management and operates from Stoughton, Massachusetts.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
